The funds will support Phase 2 testing of a drug the company believes to be able to safety home in on AMPA receptors, an ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

A dramatic pullback in public biotech investment catalyzed by economic and regulatory upheaval is putting even more stress on ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of ...

The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about how gene therapies will be regulated under new FDA leadership.

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...